Natera to collaborate with MGH on breast cancer trial

By staff writers

August 27, 2020 -- Natera plans to collaborate with Massachusetts General Hospital (MGH) on a clinical trial that will test the effectiveness of ribociclib (Kisqali) in combination with endocrine therapy for treatment of estrogen receptor-positive breast cancer.

The study will include patients with localized post-menopausal breast cancer with detectable circulating tumor DNA (ctDNA) after surgery, and will assess tumor response to ribociclib treatment in combination with endocrine therapy compared to endocrine therapy alone, the company said. The trial will use Natera's Signatera ctDNA test to identify eligible study participants.

Natera touts data supporting personalized ctDNA testing
Natera is highlighting clinical data that supports the efficacy of personalized circulating tumor DNA (ctDNA) testing for oligometastatic colorectal cancer.
Natera files patent lawsuit against Progenity
Natera has filed a lawsuit against Progenity for infringing six U.S. patents.
New technique improves Natera's organ transplant test
Natera has launched a new technique that enhances results from Prospera, the company's donor-derived cell-free DNA organ transplant laboratory-developed...
Natera's prenatal testing coverage expands
A national insurer has expanded coverage of Natera's Panorama cell-free DNA and noninvasive prenatal test to all pregnant women, regardless of age. Natera...
Natera releases pricing for Prospera cell-free DNA test
Cell-free DNA testing company Natera has released pricing for its Prospera donor-derived cell-free DNA organ transplant laboratory-developed test.

Copyright © 2020

Last Updated ls 8/27/2020 3:30:51 PM